20061206
 Roche Holding AG: Use of Halozyme's Technology Could Cost Up to $581 Million   The Wall Street Journal,  Dec 7, 2006  Roche Holding AG said it will pay as much as $581 million to Halozyme Therapeutics Inc. to use the U.S. biopharmaceutical company's technology that enhances the ability of a drug to pass through the skin.   
